Company Overview
Medifast, Inc., through its subsidiaries, operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions for weight loss in the United States. The company offers weight loss, weight management, and healthy living products comprising bars, cereals, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, soups, amino acid blends, whey protein, hot beverages, brownies, and mini meals under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories, as well as daily nutrient packs, including multivitamins, minerals, and omega-3 fatty acid supplements. It also provides lifestyle plans, which provides a targeted reset of the body's metabolism by activating strong and targeted fat burn; Optimal Weight 4 & 2 & 1 Plan and Optimal Weight 4 & 2 ACTIVE Plan, which is designed for clients who want to continue eating all food groups or want a flexible meal plan to achieve a healthy weight; OPTAVIA Optimization Plan, a personalized approach to help clients' long-term weight management; and OPTAVIA GLP-1 Nutrition Support Plan, a nutritional companion to GLP-1 medication that allows clients to focus on weight loss. In addition, the company offers metabolic synchronization, a science that reverses metabolic dysfunction through a targeted reset of the body's metabolism. It markets its products through point-of-sale transactions executed over an e-commerce platform. The company serves health and wellness consumers. The company was formerly known as Healthrite, Inc. and changed its name to Medifast, Inc. in May 2001. Medifast, Inc. was incorporated in 1980 and is headquartered in Baltimore, Maryland.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.14.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $385.79M (-36.0% YoY); net profit $-18.67M.
- Trailing 12 Months Year-on-year growth — revenue -27.6%, earnings -993.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 5.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 5.63% |
| 1 Year: | -27.60% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -992.97% |
Stock Price Performance
| 1 Year: | -7.81% |
| 6 Months: | +17.27% |
| 3 Months: | +4.38% |
| 1 Month: | +4.21% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)64.42 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Consumer Cyclical).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MED Medifast, Inc. R2K | 12.63 | -5.42 | $141.21M | 0.00% | -6.93% | -12.42% | 5.63% | - |
| 2 | AMZN Amazon.com, Inc. NDXSPXR3KAITECH | 258.51 | 20.78 | $2.79T | 0.00% | 13.33% | 30.56% | 24.04% | 32.72% |
| 3 | TSLA Tesla, Inc. NDXSPXR3KAI | 354.29 | 325.04 | $1.40T | 0.00% | 4.10% | 4.67% | 52.40% | 39.39% |
| 4 | HD The Home Depot, Inc. SPXR3K | 321.05 | 22.79 | $320.12B | 2.67% | 28.75% | 128.38% | 4.06% | 6.35% |
| 5 | BABA Alibaba Group Holding Limited AITECH | 113.24 | 17.37 | $271.42B | 0.83% | 4.16% | 9.22% | 5.62% | 12.49% |
| 6 | TM Toyota Motor Corporation | 197.39 | 8.85 | $233.73B | 3.30% | 5.24% | 12.40% | 10.91% | 16.22% |
| 7 | MCD McDonald's Corporation SPXR3K | 255.69 | 20.75 | $181.67B | 2.69% | 22.47% | - | 0.92% | 7.33% |
| 8 | BKNG Booking Holdings Inc. NDXSPXR3K | 193.29 | 21.48 | $149.78B | 0.78% | 70.23% | -96.88% | 16.93% | 22.07% |
| 9 | TJX The TJX Companies, Inc. SPXR3K | 132.08 | 25.70 | $145.91B | 1.18% | 21.26% | 61.25% | 6.84% | 8.48% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 417.60M | 453.33M | 390.40M | 348.98M | 296.19M | 235.87M | 174.74M | 168.56M | 140.16M | - | 105.56M | 89.41M | 75.10M | 76.04M | 76.38M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.91M | 27.25M | 22.96M | 24.29M | 22.99M |
| Gross Profit | 49.16M | 45.22M | 53.19M | 53.23M | 52.16M | 47.08M | 52.89M | 57.61M | 58.18M | 59.13M | 74.81M | 88.80M | 107.20M | 109.09M | 125.15M | 140.71M | 142.93M | 128.07M | 135.24M | 159.30M | 204.04M | 199.24M | 248.55M | 293.71M | 307.06M | 302.29M | 321.68M | 282.85M | 246.39M | 210.72M | 177.38M | 127.29M | 123.44M | 105.67M | - | 76.64M | 62.16M | 52.14M | 51.76M | 53.40M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 77.71M | 66.24M | 59.94M | 55.05M | 57.72M |
| Operating Income | 7.97M | - | 6.27M | 5.02M | 8.95M | - | 8.61M | 11.31M | 10.23M | - | 14.68M | 17.11M | 17.47M | - | 24.71M | 27.36M | 20.26M | - | 23.53M | 28.10M | 44.56M | - | 52.80M | 61.43M | 55.17M | 55.09M | 48.96M | 48.16M | 53.51M | 38.71M | 25.51M | 7.94M | -7.88M | 2.11M | - | -1.07M | -4.08M | -7.80M | -3.29M | -4.33M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.98M | -629.00K | -4.34M | 188.00K | -881.00K |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.88M | -2.66M | -6.38M | -1.94M | -2.99M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 395.00K | -396.00K | 11.74M | 181.00K | 109.00K |
| Net Income | 5.51M | 3.86M | 4.26M | 3.40M | 6.07M | 4.11M | 6.14M | 7.58M | 6.69M | 7.31M | 12.22M | 14.13M | 13.78M | 15.65M | 20.75M | 21.38M | 15.90M | 19.88M | 18.48M | 21.93M | 34.45M | 27.99M | 41.06M | 46.96M | 41.98M | 41.78M | 39.11M | 36.16M | 39.97M | 30.28M | 23.13M | 8.32M | -8.15M | 1.13M | - | 2.48M | -2.26M | -18.12M | -2.12M | -3.10M |
| Diluted EPS | 0.46 | 0.33 | 0.36 | 0.29 | 0.51 | 0.34 | 0.51 | 0.63 | 0.55 | 0.60 | 1.01 | 1.16 | 1.14 | 1.30 | 1.70 | 1.75 | 1.32 | 1.66 | 1.56 | 1.86 | 2.91 | 2.36 | 3.46 | 3.96 | 3.56 | 3.59 | 3.42 | 3.27 | 3.67 | 2.77 | 2.12 | 0.76 | -0.75 | 0.10 | - | 0.22 | -0.21 | -1.65 | -0.19 | -0.28 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 169.74M | 257.55M | 298.19M | 318.57M | 324.05M | 285.29M | 272.77M | 274.53M | 301.56M | 501.00M | 713.67M | 934.84M | - | 1.60B | 1.07B | 602.46M | 385.79M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 458.16M | 296.20M | 157.84M | 110.60M |
| Gross Profit | 124.39M | 192.47M | 224.50M | 235.91M | 240.57M | 209.21M | 201.31M | 205.66M | 227.81M | 379.90M | 536.86M | 697.82M | - | 1.14B | 775.85M | 444.62M | 275.19M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 955.61M | 649.45M | 441.75M | 289.40M |
| Operating Income | 18.50M | 31.64M | 27.38M | 27.14M | 38.41M | 30.25M | 28.68M | 26.86M | 39.63M | 69.06M | 91.04M | 134.16M | - | 184.81M | 126.40M | 2.88M | -14.21M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | 195.74M | 139.51M | 15.59M | 29.00K |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 701.00K | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | 184.06M | 128.80M | 3.79M | -5.64M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 40.49M | 29.38M | 1.70M | 13.03M |
| Net Income | 11.36M | 19.61M | 18.54M | 15.88M | 23.97M | 13.18M | 20.06M | 17.84M | 27.72M | 55.79M | 77.92M | 102.86M | - | 143.57M | 99.42M | 2.09M | -18.67M |
| Diluted EPS | 0.77 | 1.35 | 1.31 | 1.16 | 1.73 | 1.03 | 1.66 | 1.49 | 2.29 | 4.62 | 6.43 | 8.68 | - | 12.73 | 9.10 | 0.19 | -1.70 |
| R&D Expense | - | - | - | - | - | 1.30M | 1.80M | 2.00M | 1.50M | 2.20M | 2.70M | 2.80M | 4.40M | 4.50M | 4.60M | 4.60M | 4.30M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 94.06M | 105.67M | 130.25M | 132.65M | 115.91M | 116.12M | 121.22M | 145.93M | 169.43M | 194.65M | 276.08M | 398.33M | 316.21M | 309.91M | 284.21M | 247.97M |
| Total Equity | 34.07M | 47.82M | 71.96M | 73.40M | 90.79M | 98.42M | 80.48M | 88.58M | 96.02M | 106.56M | 109.11M | 104.83M | 157.25M | 202.47M | 155.04M | 201.48M | 210.11M | 198.92M |
| Cash & Equivalents | 973.00K | 10.60M | 17.16M | 14.26M | 39.94M | 36.38M | 24.46M | 42.04M | 52.44M | 75.08M | 81.36M | 76.97M | 163.72M | 104.18M | 87.69M | 94.44M | 90.93M | 89.30M |
| Long Term Debt | - | - | 4.65M | 3.34M | 3.11M | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 22.10M | 32.26M | 39.47M | 34.23M | 35.43M | 27.53M | 25.20M | 37.35M | 60.32M | 89.82M | 118.84M | 195.85M | 161.17M | 108.43M | 74.10M | 49.05M |
| Current Liabilities | - | - | 15.96M | 20.26M | 28.75M | 27.10M | 26.94M | 23.56M | 24.42M | 37.14M | 60.32M | 79.39M | 111.35M | 169.83M | 140.89M | 92.30M | 64.16M | 42.96M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 19.16M | 28.77M | 34.87M | 40.26M | 42.36M | 25.54M | 29.41M | 25.35M | 43.24M | 60.82M | 84.26M | 145.20M | - | 194.57M | 147.66M | 24.48M | 6.86M |
| Investing Cash Flow | -8.62M | -23.54M | -16.87M | -11.66M | -22.60M | -2.52M | -189.00K | -2.04M | -3.16M | -1.20M | -6.33M | -1.28M | - | -11.41M | -61.05M | -26.52M | -7.93M |
| Financing Cash Flow | -908.00K | 1.33M | -20.90M | -2.92M | -23.31M | -34.94M | -11.73M | -12.92M | -17.36M | -53.33M | -82.32M | -57.14M | - | -199.58M | -79.79M | -1.51M | -564.00K |
| Capital Expenditure | -5.12M | -12.05M | -14.27M | -8.13M | -11.39M | -7.02M | -2.82M | -2.88M | -3.24M | -4.94M | -10.06M | -5.89M | - | -16.68M | -6.48M | -7.45M | -5.61M |
| Free Cash Flow | 14.04M | 16.71M | 20.60M | 32.14M | 30.97M | 18.51M | 26.59M | 22.47M | 39.99M | 55.88M | 74.20M | 139.31M | - | 177.89M | 141.17M | 17.02M | 1.25M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -16.43M | 6.82M | -3.56M | -1.63M |
| Share Buybacks | 102.00K | 35.00K | 20.39M | 2.76M | 20.08M | 33.89M | 10.52M | - | - | 30.00M | 33.11M | 5.00M | 56.00M | 126.44M | 3.60M | 0 | 0 |
| Dividends Paid | - | - | - | - | - | - | - | 11.89M | 15.39M | 23.16M | 35.40M | 53.19M | 63.86M | 71.62M | 73.02M | 715.00K | 195.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 73.3% | 74.7% | 75.3% | 74.1% | 74.2% | 73.3% | 73.8% | 74.9% | 75.5% | 75.8% | 75.2% | 74.6% | - | 71.3% | 72.4% | 73.8% | 71.3% |
| Operating Margin % | 10.9% | 12.3% | 9.2% | 8.5% | 11.9% | 10.6% | 10.5% | 9.8% | 13.1% | 13.8% | 12.8% | 14.4% | - | 11.6% | 11.8% | 0.5% | -3.7% |
| Net Margin % | 6.7% | 7.6% | 6.2% | 5.0% | 7.4% | 4.6% | 7.4% | 6.5% | 9.2% | 11.1% | 10.9% | 11.0% | - | 9.0% | 9.3% | 0.3% | -4.8% |
| ROE % | 23.8% | 27.3% | 25.3% | 17.5% | 24.4% | 16.4% | 22.6% | 18.6% | 26.0% | 51.1% | 74.3% | 65.4% | - | 92.6% | 49.3% | 1.0% | -9.4% |
| ROCE % | - | 40.5% | 32.1% | 26.7% | 36.4% | 34.0% | 31.0% | 27.7% | 36.4% | 63.3% | 79.0% | 81.4% | - | 105.4% | 58.1% | 1.3% | -6.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Renaissance Technologies, LLC | 6.96% | 778.61K | $9.48M |
| 2 | Steamboat Capital Partners, Llc | 6.32% | 706.70K | $8.61M |
| 3 | Two Sigma Investments, LP | 4.31% | 481.38K | $5.86M |
| 4 | Vanguard Capital Management LLC | 3.99% | 446.61K | $5.44M |
| 5 | Charles Schwab Investment Management, Inc. | 3.55% | 397.00K | $4.84M |
| 6 | Blackrock Inc. | 3.30% | 369.50K | $4.50M |
| 7 | Dimensional Fund Advisors LP | 3.25% | 363.39K | $4.43M |
| 8 | American Century Companies Inc | 2.85% | 318.91K | $3.88M |
| 9 | Morgan Stanley | 2.62% | 292.51K | $3.56M |
| 10 | Goldman Sachs Group Inc | 2.17% | 243.09K | $2.96M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MED
Medifast (NYSE:MED) Stock Crosses Above 200 Day Moving Average - Time to Sell? - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxQQUJrNm9kSUZzTl9aRzREcmVDMTVTTnVuUmlHQWNfTTJQQnRPV2N5SmVEZXdKeFNwaWJ6eGV6NVl6SXFWSzcwZ29OMTRtcktEMjJ0NmFYRVc5Q1lEVndKTElYd2prdFZtbE1OTDJDQlJpeVY1RVoxakRfRTlIbXByR3FZOGQtWnNkWVBVZU…
3 Reasons to Sell MED and 1 Stock to Buy Instead - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxOUUZwQkJXU0JOd1NuS2RwaHluVWJVZmRCNnZJUGZkNlEzZVNBWXBSX1NnUi1nMk1ReHpoaVpDaU94Y3FSUXRVc0dGTFZteHVqZll1RS1kSTc1UF9XV2J3aHJPN3g1OFpYTlYySEJZd091dzV0UUxNQklpeUFIVXdLcGh1dE9GVl9ENWlvaF…
Medifast director Kiai Parsa buys $529k in MED stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNTHJoLUp6Y1k0NEtIbkF5dW9yd2tRT09EZi1NNGFWQjJYZm1SYzAtVmFvSVBsenBYR0JUNVdTSG9LaGFFbWQzX0Zhc0RZQm00S0hkWVM1N1ZnUzNKaEhaOW8zVHYzQUV0dzRlcXgtaDRMX3RYazdkSk45U1hFcmZreFlidW5JUnl6czAyMk…
MED - Finviz
<a href="https://news.google.com/rss/articles/CBMiREFVX3lxTE4zQ1BVTEdBaWxpeUR6QVNyYWNMbGxrMlFuSElIemxXZmhOZERzZ3VPa2xKM3NIbDVjU0V3dzFTc1FVWVhr?oc=5" target="_blank">MED</a> <font color="#6f6f6f">Finviz</font>…
$MED stock is up 21% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNX3Z6TkY3RXRNM2RsS3FkeXE5SGl6a2lEOXRqS01YQTltMVZfdnFtbFN0QW1oNF9CS2ZpVzBhUGJYQlFTXy1WRThUcXdOQWVWcjJfWGRrUHZqckpJQUl2amtWRU5vRkdrSm01ZVhrUVhSWW1uSnJiVC1vLWIydzcxZXd2OVFuM1ZoLXp0X3…
6 Best Healthcare Stocks for 2026 and How to Invest - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFAzYldfXzNGYzFPZGREZFpucVQzd0lSLTdOR1RRRDgtSHdTcG5iVi1ZdDhYVWs3a2lCM1hsRWhWWDg0TWRERHFkSmk1WFJlY1dTQk96VndJZV9TMlZkTUR3eGVnYk92MUhnaDJrY01yVkRTM25VYk5NRHZR?oc=5" target="_blank">6 B…
MED — Frequently Asked Questions
What is the current share price of Medifast, Inc. (MED)?
As of 2026-09-07 16:24 PDT, Medifast, Inc. (MED) trades at $12.63 on NYSE. Its 52-week range is $9.45 to $14.57.
What is the market capitalisation of MED?
Medifast, Inc. (MED) has a market capitalisation of $141.21M on NYSE.
What is the P/E ratio of MED?
MED trades at a trailing price-to-earnings (P/E) ratio of -5.42. The industry average P/E is 19.51. Its price-to-book (P/B) ratio is 0.66.
What is the return on equity (ROE) of MED?
MED has a return on equity (ROE) of -12.42%. Its return on capital employed (ROCE) is -6.93%.
Is MED a good stock to buy?
This page provides a data-driven analysis of Medifast, Inc. (MED), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.